| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$57.3M | ROE | −126.85% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $21.6M | Trading Days | 1229 |
| 52W High | 4.99 |
| 52W Low | 0.57 |
| % Off High | −87.68% |
| YTD | −18.01% | 1Y | −83.56% |
| 3Y | −90.79% | 5Y | −98.40% |
| Since incept. (ann.) | −51.75% |
| Ann. Volatility (1Y) | 104.01% | Ann. Volatility (3Y) | 143.76% |
| Sharpe (1Y) | −1.13 | Sharpe (3Y) | 0.11 |
| Max Drawdown (1Y) | −87.85% | Max Drawdown (3Y) | −96.79% |
| Beta (3Y, vs SPY) | 5.47 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | $21.8M | — |
| CELU | Celularity Inc | $22.0M | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $20.8M | — |
| NEUP | Neuphoria Therapeutics Inc. | $20.6M | — |
| PYRGF | PyroGenesis Canada Inc. | $22.8M | — |
| AYTU | AYTU BIOPHARMA, INC | $22.9M | — |
| TVRD | Tvardi Therapeutics, Inc. | $22.9M | — |
| BRNS | Barinthus Biotherapeutics plc. | $23.3M | — |
| CLRB | Cellectar Biosciences, Inc. | $20.0M | — |
| CRVO | CervoMed Inc. | $23.7M | 0.0 |
| MRKR | Marker Therapeutics, Inc. | $19.7M |
| — |
| TXMD | TherapeuticsMD, Inc. | $23.8M | — |
